Brief: Quantum Genomics Announces Trial Design For Quorum, Its Phase IIB Study In Heart Failure

Quantum Genomics SA

26/06/2018 17:11

June 26 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * QUANTUM GENOMICS ANNOUNCES TRIAL DESIGN FOR QUORUM, ITS
PHASE
IIB STUDY IN HEART FAILURE
    * PHASE IIB CLINICAL STUDY ASSESSING THE EFFICACY AND SAFETY
OF
FIRIBASTAT COMPARED TO RAMIPRIL IN PATIENTS WITH REDUCED
EJECTION FRACTION FOLLOWING ACUTE MYOCARDIAL INFARCTION (AMI)
    * LAUNCH BY THE END OF 2018 IN EUROPE AND IN THE US,
EXPECTED
RESULTS IN MID-2020
    * FIRIBASTAT OFFERS PROMISING PERSPECTIVES IN THE TREATMENT
OF
HEART FAILURE

Source text for Eikon:  ID:nACT53921 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))